The ICH Q11 Guideline on Development and Manufacture of Drug Substances ( Chemical Entities and Biotechnological/Biological Entities). Step 3. Transmission to CHMP. May Adoption by CHMP for release for ICH guideline Q11 on development and manufacture of drug substances . endorsed by the ICH Assembly at Step 4 of the ICH process, August Do the ICH Q11 general principles for selection of starting materials apply to the.
|Published (Last):||28 May 2016|
|PDF File Size:||16.45 Mb|
|ePub File Size:||13.25 Mb|
|Price:||Free* [*Free Regsitration Required]|
This resulted in questions and additional demands by the agencies, thereby delaying the approval processes. It remains to be seen whether stdp will speed up approval processes. ICH Q11, section 9 describes basic scientific and risk-based concepts for the evaluation of post-approval changes to the starting material.
This means impurities which are not purged over multiple synthesis steps and possibly remain in the final product e. The distinction between these two terms plays an important role in ICH Q11 insofar as that an applicant does not have to justify the use of a “commercially available” substance as a starting material in the dossier – on the contrary to “custom synthesised” compounds; those are subject to the regulations of ICH Q The selection of a starting material for the synthesis of an active substance and its justification is often one of the most crucial steps in the approval process.
The term “custom synthesised” is not defined in ICH Q11; it is generally understood to be a substance which has been synthesised specifically for pharmaceutical manufacture and in consideration of a customers’ requirements.
Yes, the terms are synonymous. The criteria for this are outlined in the ICH Q11 guideline – however, not in a sufficiently precise manner. In cases such as this, a detailed description of all synthesis q1 in which these impurities are formed may be forgone in the dossier section 3.
The same goes for intermediates that do not count as “commercially available” according to ICH Q In that case, the dossier has to stel a control strategy and justify the choice of starting material.
Residual risks in regards to the drug substance quality are to be assessed. However, the regulations in ICH Q7 relate to the GMP compliant manufacture of active substances, not the procedure of selecting and justifying starting materials. These concepts should logically be applied to steps upstream of the starting material as well.
Changes in earlier synthesis steps upstream must be made in accordance with the quality assurance system of the applicant. When related substances are at a level that exceeds those limits, an impact on the impurity profile is to be expected.
ICH Q11 Q&A reaches Step 4
In order to establish a common understanding in regards to the information on starting materials in module 3 section 3. In total, the document contains 16 questions and stwp corresponding answers, all of which refer specifically to the guideline ICH Q11, chapter 5 ” Selection of Starting Materials and Source Materials “.